JPH062073B2 - Hyaluronic acid manufacturing method - Google Patents
Hyaluronic acid manufacturing methodInfo
- Publication number
- JPH062073B2 JPH062073B2 JP8094985A JP8094985A JPH062073B2 JP H062073 B2 JPH062073 B2 JP H062073B2 JP 8094985 A JP8094985 A JP 8094985A JP 8094985 A JP8094985 A JP 8094985A JP H062073 B2 JPH062073 B2 JP H062073B2
- Authority
- JP
- Japan
- Prior art keywords
- hyaluronic acid
- culture solution
- culture
- added
- producing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims description 59
- 229920002674 hyaluronan Polymers 0.000 title claims description 59
- 229960003160 hyaluronic acid Drugs 0.000 title claims description 59
- 238000004519 manufacturing process Methods 0.000 title claims description 25
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 claims description 22
- 239000004094 surface-active agent Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 11
- 238000012258 culturing Methods 0.000 claims description 10
- 108010014251 Muramidase Proteins 0.000 claims description 7
- 102000016943 Muramidase Human genes 0.000 claims description 7
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 7
- 239000004325 lysozyme Substances 0.000 claims description 7
- 229960000274 lysozyme Drugs 0.000 claims description 7
- 235000010335 lysozyme Nutrition 0.000 claims description 7
- 244000005700 microbiome Species 0.000 claims description 6
- 239000000243 solution Substances 0.000 description 53
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 25
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 14
- 229910000160 potassium phosphate Inorganic materials 0.000 description 12
- 235000011009 potassium phosphates Nutrition 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 229920002385 Sodium hyaluronate Polymers 0.000 description 10
- 229940010747 sodium hyaluronate Drugs 0.000 description 10
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 7
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 7
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 7
- 238000012136 culture method Methods 0.000 description 7
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 7
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 7
- 239000011565 manganese chloride Substances 0.000 description 7
- 235000002867 manganese chloride Nutrition 0.000 description 7
- 229940099607 manganese chloride Drugs 0.000 description 7
- 235000010265 sodium sulphite Nutrition 0.000 description 7
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 7
- 235000019345 sodium thiosulphate Nutrition 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 239000001888 Peptone Substances 0.000 description 6
- 108010080698 Peptones Proteins 0.000 description 6
- 229940041514 candida albicans extract Drugs 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 235000019319 peptone Nutrition 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 235000012424 soybean oil Nutrition 0.000 description 6
- 239000003549 soybean oil Substances 0.000 description 6
- 239000012138 yeast extract Substances 0.000 description 6
- 241000194048 Streptococcus equi Species 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 235000014103 egg white Nutrition 0.000 description 4
- 210000000969 egg white Anatomy 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000120569 Streptococcus equi subsp. zooepidemicus Species 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000002101 lytic effect Effects 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- CKVCJXCLQZTFQC-UHFFFAOYSA-N 4-(3-ethyloctan-3-yloxy)-4-oxo-3-sulfobutanoic acid Chemical compound CCCCCC(CC)(CC)OC(=O)C(S(O)(=O)=O)CC(O)=O CKVCJXCLQZTFQC-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000047703 Nonion Species 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 241000264435 Streptococcus dysgalactiae subsp. equisimilis Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
【発明の詳細な説明】 本発明はヒアルロン酸生成能を有する微生物(以下、ヒ
アルロン酸生産菌という。)によるヒアルロン酸の製造
法に関する。さらに詳しくは溶菌酵素または溶菌酵素お
よび界面活性剤を添加した培養液でヒアルロン酸生産菌
を培養し、ヒアルロン酸を該培養液中に生成、蓄積せし
め、これを採取することによるヒアルロン酸の製造法に
関する。The present invention relates to a method for producing hyaluronic acid by a microorganism capable of producing hyaluronic acid (hereinafter referred to as hyaluronic acid-producing bacterium). More specifically, a method for producing hyaluronic acid by culturing a hyaluronic acid-producing bacterium in a culture solution containing a lytic enzyme or a lysing enzyme and a surfactant, producing and accumulating hyaluronic acid in the culture solution, and collecting the hyaluronic acid. Regarding
ヒアルロン酸は関節、硝子体、臍帯、軟骨、皮膚、鳥類
のとさかなどの結合組織中にその構成成分として存在
し、組織の柔軟性、構造維持、細胞の代謝調節などに重
要な機能を果たしている。また、該ヒアルロン酸は非常
に大きい高分子物質であり、その溶液は強い粘弾性を持
ち、保水作用を有するところから、化粧品、創傷治療
剤、眼薬、関節炎治療薬として広い用途がある。Hyaluronic acid exists as a constituent component in connective tissues such as joints, vitreous body, umbilical cord, cartilage, skin, and avian crest, and plays an important function in tissue flexibility, structure maintenance, and cell metabolism regulation. . In addition, the hyaluronic acid is a very large polymer substance, and its solution has a strong viscoelasticity and a water-retaining action, so that it has wide application as a cosmetic, a wound treatment agent, an eye drop, and an arthritis remedy.
従来、該ヒアルロン酸は工業的にはにわとりのとさか、
牛の目の硝子体、もしくは臍帯または鯨の軟骨などから
抽出法により得られている。しかし、これら生体から抽
出法により得たヒアルロン酸は蛋白質やコンドロイチン
等のムコ多糖と複合体を形成しているので、分離精製に
複雑な工程を必要とし、またヒアルロニダーゼが混在す
ることが多いので、抽出、精製工程中で該ヒアルロン酸
が分解されて分子量が低下し、粘度および保水性が低く
なるといつた欠点がある。このため培養法によりヒアル
ロン酸を生産する試みが特開昭58−56692号公報
に開示されている。Conventionally, the hyaluronic acid is industrially chicken-like,
It is obtained by extraction from the vitreous of cattle eyes, umbilical cord or cartilage of whales. However, hyaluronic acid obtained from these living organisms by an extraction method forms a complex with a mucopolysaccharide such as protein or chondroitin, and therefore requires a complicated step for separation and purification, and since hyaluronidase is often mixed, When the hyaluronic acid is decomposed during the extraction and purification steps to lower the molecular weight and lower the viscosity and water retention, there are some drawbacks. Therefore, an attempt to produce hyaluronic acid by a culture method is disclosed in JP-A-58-56692.
本発明者はヒアルロン酸の製造にかかわる上述の問題点
を解決するべく鋭意研究し、ヒアルロン酸生産菌を培養
するにあたり、該培養液に血清を添加した培養液を用い
ることにより、該ヒアルロン酸の生産性が大巾に高まる
ことを見い出し、特願昭59−185150号として提
案した。しかしながら、この方法は血清がロツト間によ
り品質にばらつきがあり、かつ他の培地材料にくらべて
高価なため、ヒアルロン酸の製造コストが高くなること
が否めない。The present inventor has conducted diligent research to solve the above-mentioned problems associated with the production of hyaluronic acid, and in culturing a hyaluronic acid-producing bacterium, by using a culture solution in which serum is added to the culture solution, It was found that productivity would be greatly increased, and it was proposed as Japanese Patent Application No. 59-185150. However, this method cannot be denied that the production cost of hyaluronic acid is high because the quality of serum varies from lot to lot and is more expensive than other medium materials.
本発明者は安価にかつヒアルロン酸の生産性を大巾に高
めることのできる製造方法について鋭意研究をつづけ
た。その結果、ヒアルロン酸生産菌を培養するに際し、
該培養液に溶菌酵素または溶菌酵素および界面活性剤を
添加した培養液を用いてヒアルロン酸生産菌を培養する
ことにより、製造コストを低下させ、かつヒアルロン酸
の生産性を大巾に高めることができることを見い出し、
この知見にもとづいて本発明を完成した。The present inventor has conducted earnest research on a production method which can significantly increase the productivity of hyaluronic acid at low cost. As a result, when culturing hyaluronic acid-producing bacteria,
By culturing a hyaluronic acid-producing bacterium using a culture solution obtained by adding a lytic enzyme or a lytic enzyme and a surfactant to the culture solution, the production cost can be reduced and the productivity of hyaluronic acid can be significantly increased. Find out what you can do,
The present invention has been completed based on this finding.
本発明で用いる溶菌酵素および界面活性剤はロツト間の
ばらつきがほとんどないので、常に一定の品質および生
産量が確保できる。Since the lytic enzyme and the surfactant used in the present invention have little variation among the lots, it is possible to always ensure a constant quality and production amount.
以上の記述から明らかなように、本発明の目的は、ヒア
ルロン酸の生産性を安定かつ大巾に高め、しかも安価に
ヒアルロン酸を製造する方法を提供することである。As is clear from the above description, an object of the present invention is to provide a method for stably and significantly increasing the productivity of hyaluronic acid, and at a low cost, for producing hyaluronic acid.
本発明は以下の構成を有する。The present invention has the following configurations.
(1)溶菌酵素を添加してなる培養液にて、ヒアルロン
酸生成能を有する微生物を培養して、該培養液中にヒア
ルロン酸を生育蓄積せしめ、これを採取することを特徴
とするヒアルロン酸の製造法。(1) Hyaluronic acid characterized by culturing a microorganism having a hyaluronic acid-producing ability in a culture solution to which a lytic enzyme is added, to grow and accumulate hyaluronic acid in the culture solution, and to collect this Manufacturing method.
(2)溶菌酵素および界面活性剤を添加してなる培養液
にて、ヒアルロン酸生成能を有する微生物を培養して、
該培養液中にヒアルロン酸を生成蓄積せしめ、これを採
取することを特徴とするヒアルロン酸の製造法。(2) Culturing a microorganism capable of producing hyaluronic acid in a culture solution containing a lytic enzyme and a surfactant,
A method for producing hyaluronic acid, characterized in that hyaluronic acid is produced and accumulated in the culture solution, and this is collected.
本発明に用いるヒアルロン酸生産菌としては、 ストレプトコツカス・ピオゲネス (Streptococcus pyogenes), ストレプトコツカス・エクイ (Streptococcus equi), ストレプトコツカス・エクイシミリス (Streptococcus equisimilis) ストレプトコツカス・デイスガラクテイエ (Streptococcus dysgalactiae), ストレプトコツカス・ズーエピデミカス (Streptococcus zooepidemicus), パスツレラ・マルトシダ (Pasteurella multocida), などがあげられる。Examples of hyaluronic acid-producing bacteria used in the present invention include Streptococcus pyogenes, Streptococcus equi, and Streptococcus equisimilis Streptococcus ), Streptococcus zooepidemicus, and Pasteurella multocida.
本発明に用いる溶菌酵素は溶菌活性をもつすべての酵素
が利用できるが、リゾチームが最も好ましい。培養液に
添加する該溶菌酵素の量は特に制限されないが、好まし
くは、培養液1当り100〜2500単位、より好ま
しくは300〜20000単位、最も好ましくは500
〜1000単位である。溶菌酵素の添加量が少なすぎる
とヒアルロン酸の生成、蓄積が少なくなり、また該添加
量が多すぎると溶菌作用が大きくなり、ヒアルロン酸生
産菌の生育が阻害されるので好ましくない。As the lytic enzyme used in the present invention, all enzymes having lytic activity can be used, but lysozyme is most preferable. The amount of the lytic enzyme added to the culture solution is not particularly limited, but is preferably 100 to 2500 units, more preferably 300 to 20000 units, and most preferably 500 per culture solution.
~ 1000 units. If the amount of the lytic enzyme added is too small, the production and accumulation of hyaluronic acid will decrease, and if the amount added is too large, the lytic action will increase and the growth of the hyaluronic acid-producing bacteria will be impaired.
さらに該溶菌酵素の添加時期は、添加しようとする培養
液を加圧蒸気滅菌法などで滅菌したのち、冷却し、温度
が45℃以下になつた時点で無菌的に培養液に添加する
のが好ましい。Further, the lytic enzyme is added at the time when the culture solution to be added is sterilized by a pressure steam sterilization method or the like and then cooled, and aseptically added to the culture solution when the temperature reaches 45 ° C or lower. preferable.
本発明に用いる界面活性剤としては、臭化セチルトリメ
チルアンモニウム、塩化セチルピリジニウム、ツイーン
80(商品名、花王化学(株)製)、ツイーン90(商
品名、花王化学(株)製)、ラウリル硫酸ナトリウム、
トライトンX−100(商品名、ロームアンドハース
(株)製)、スパン80(商品名、花王化学(株)
製)、スパン90(商品名、花王化学(株)製)、ノニ
オン(商品名、日本油脂(株)製)、スルホコハク酸ジ
エチルヘキシルなどをあげることができる。培養液に加
える該界面活性剤の添加量は好ましくは培養液1当り
0.5〜10gで、より好ましくは0.5〜3g、最も
好ましくは1.0〜2.0gである。該界面活性剤は培
養液を加圧蒸気で滅菌する前に培養液に添加する。As the surfactant used in the present invention, cetyltrimethylammonium bromide, cetylpyridinium chloride, Tween 80 (trade name, manufactured by Kao Chemical Co., Ltd.), Tween 90 (trade name, manufactured by Kao Chemical Co., Ltd.), lauryl sulfate sodium,
Triton X-100 (trade name, manufactured by Rohm and Haas Co., Ltd.), Span 80 (trade name, Kao Chemical Co., Ltd.)
Manufactured by K.K.), Span 90 (trade name, manufactured by Kao Chemical Co., Ltd.), nonion (trade name, manufactured by NOF CORPORATION), diethylhexyl sulfosuccinate, and the like. The amount of the surfactant added to the culture solution is preferably 0.5 to 10 g, more preferably 0.5 to 3 g, and most preferably 1.0 to 2.0 g per culture solution. The surfactant is added to the culture solution before sterilizing the culture solution with pressurized steam.
本発明にあつては、溶菌酵素または溶菌酵素および界面
活性剤を添加する前の培養液の成分としては、ヒアルロ
ン酸生産菌を培養するおに通常用いられる培養液を用い
ればよく、例えばブドウ糖2.0〜3.0%、リン酸1
カリウム0.3%、リン酸2カリウム0.2%、チオ硫
酸ナトリウム0.01%、硫酸マグネシウム7水塩0.
01%、亜硫酸ナトリウム0.002%、塩化コバルト
0.001%、塩化マンガン0.001%、消泡剤0.
5%を含む成分でpH6.0〜8.5の培養液を用いるこ
とができる。(ただし%はいずれも重量をg、容量を
とした重量/容量%を表わし、以下特にことわらない限
り%は上述の重量/容量%を表わす。) 本発明のヒアルロン酸の製造は、まず溶菌酵素および界
面活性剤を含まない培養液または界面活性剤を含み、溶
菌酵素を含まない培養液を加圧蒸気滅菌法などで滅菌し
たのち、冷却し、該培養液の温度が45℃以下になつた
時点で溶菌酵素を無菌的に該培養液に添加し、ついでヒ
アルロン酸生産菌を無菌的に該培養液に接種する。つい
でヒアルロン酸生産菌を接種した培養液を通気撹拌もし
くは静置して温度25℃〜40℃、好ましくは30℃〜
35℃の温度で、pH6.5〜8.0、好ましくは7.0
に制御してヒアルロン酸生産菌を1〜2日間培養したの
ち、該培養液にさらに糖成分を3%追加してさらに1〜
2日間培養してヒアルロン酸を生成、蓄積させる。その
後、該培養液を遠心分離もしくは過によつて除菌した
のち、該液を限外過もしくは透析することによつて
低分子量物質を除去する。ついで低分子量物質を除去し
た液にメタノール、エタノールなどのアルコールを添
加して、ヒアルロン酸の粗組成物を沈澱させ、該沈澱ヒ
アルロン酸を再び水に溶解させたのち、臭化セチルトリ
メチムアンモニウムを添加して該臭化セチルトリメチル
アンモニウムによる分画沈澱、ついでイオン交換クロマ
トグラフイー、ゲル過クロマトグラフイーなど公知の
精製手段によつて、生成したヒアルロン酸を精製する方
法により行なわれる。In the present invention, as a component of the culture solution before adding the lytic enzyme or the lytic enzyme and the surfactant, a culture solution generally used for culturing hyaluronic acid-producing bacteria may be used. For example, glucose 2 0.0 to 3.0%, phosphoric acid 1
Potassium 0.3%, dipotassium phosphate 0.2%, sodium thiosulfate 0.01%, magnesium sulfate heptahydrate 0.
01%, sodium sulfite 0.002%, cobalt chloride 0.001%, manganese chloride 0.001%, antifoaming agent 0.1%.
It is possible to use a culture solution having a pH of 6.0 to 8.5 with a component containing 5%. (However,% represents weight / volume% in which weight is g and volume, and unless otherwise specified,% represents the above-mentioned weight / volume%.) The hyaluronic acid of the present invention is produced by first lysing. After sterilizing a culture solution containing no enzyme and a surfactant or a culture solution containing a surfactant but not a lytic enzyme by a pressure steam sterilization method, the temperature is lowered to 45 ° C or lower after cooling. At that time, the lytic enzyme is aseptically added to the culture solution, and then the hyaluronic acid-producing bacterium is aseptically inoculated into the culture solution. Then, the culture broth inoculated with the hyaluronic acid-producing bacterium is aerated with stirring or allowed to stand, and the temperature is 25 ° C to 40 ° C, preferably 30 ° C to
At a temperature of 35 ° C, pH 6.5-8.0, preferably 7.0
The hyaluronic acid-producing bacterium is cultivated for 1 to 2 days under control to 1%, and then the sugar solution is further added with 3% to further
It is cultured for 2 days to produce and accumulate hyaluronic acid. After that, the culture solution is sterilized by centrifugation or filtration, and the low molecular weight substance is removed by ultrafiltration or dialysis of the solution. Then, alcohol such as methanol and ethanol is added to the liquid from which the low molecular weight substance has been removed to precipitate a crude composition of hyaluronic acid, and the precipitated hyaluronic acid is dissolved again in water, and then cetyltrimethyme ammonium bromide is added. Addition is carried out by fractionation precipitation with the cetyltrimethylammonium bromide, followed by purification of the produced hyaluronic acid by known purification means such as ion exchange chromatography and gel perchromatography.
本発明の溶菌酵素または溶菌酵素および界面活性剤を添
加してなる培養液を用いた培養法を用いることにより、
該溶菌酵素または溶菌酵素および界面活性剤を添加しな
い通常の培養液を用いた培養法(比較例)にくらべヒア
ルロン酸の生産性を培養液1当り4〜5倍と大巾に向
上させることができ、かつ血清を用いる培養法にくらべ
て、ヒアルロン酸の製造原価を1/20以下に下げること
が可能となつた。また、用いる溶菌酵素および界面活性
剤は、ロツト間の品質のばらつきがほとんどないので、
常に一定の品質、生産量でヒアルロン酸の製造が可能と
なり画期的なヒアルロン酸の製造法である。また本発明
により得られるヒアルロン酸は不純物の含有量がきわめ
て少なく、高純度のヒアルロン酸であり、医薬品、化粧
品の用途に好適に使用することができる。By using the culturing method using the culture solution containing the lytic enzyme or the lytic enzyme and the surfactant of the present invention,
It is possible to greatly improve the productivity of hyaluronic acid by 4 to 5 times per culture solution as compared with the culture method using an ordinary culture solution without adding the lytic enzyme or the lytic enzyme and a surfactant (Comparative Example). The production cost of hyaluronic acid can be reduced to 1/20 or less as compared with the culture method using serum. Also, the lytic enzymes and surfactants used have almost no variation in quality between lots, so
This is an epoch-making method for producing hyaluronic acid because it makes it possible to produce hyaluronic acid with consistently constant quality and production volume. The hyaluronic acid obtained by the present invention is a highly pure hyaluronic acid having a very low content of impurities, and can be suitably used for pharmaceutical and cosmetic applications.
以上記述したように本発明に係るヒアルロン酸の製造法
は安定的に純度の高いヒアルロン酸をきわめて高い生産
性で製造できる方法であることが確認された。As described above, it was confirmed that the method for producing hyaluronic acid according to the present invention can stably produce highly pure hyaluronic acid with extremely high productivity.
以下実施例および比較例により本発明を具体的に説明す
るが、本発明はこれにより限定されるものではない。The present invention will be specifically described below with reference to Examples and Comparative Examples, but the present invention is not limited thereto.
なお、本発明で用いたストレプトコツカス・ズーエピデ
ミカムは農林水産省家畜衛生試験場より入手し、ストレ
プトコツカス・エクイは東京大学医学部附属医科学研究
所より入手した。The Streptococcus zooepidemicum used in the present invention was obtained from the Animal Health Research Center of the Ministry of Agriculture, Forestry and Fisheries, and the Streptococcus equi was obtained from the Institute of Medical Science, University of Tokyo.
実施例1 ブドウ糖2.0%、酵母エキス0.5%、ペプトン1.
5%、リン酸1カリウム0.3%、リン酸2カリウム
0.2%、チオ硫酸ナトリウム0.011%、硫酸マグ
ネシウム7水塩0.01%、亜硫酸ナトリウム0.00
2%、塩化コバルト0.001%、塩化マンガン0.0
01%、大豆油0.5%からなるpH7.0の培養液1.
5を内容積3.0のミニジヤーフアーメンターに注
入し、120℃で15分間加熱滅菌し、室温まで冷却し
たのち、卵白リゾチーム0.75mg(675単位)を無
菌的に該培養液に添加し、ついでストレプトコツカス・
ズーエピデミカスの前培養液0.1を接種し、毎分3
00回転、通気量0.7vvm、温度35℃でpH7.0に
なるように自動制御して24時間培養した。その後、ブ
ドウ糖の50%水溶液100mlをさらに該培養液に無菌
的に加えて、上述の培養条件下にさらに26時間培養し
たのち、該培養液にイオン交換水3.2を加えて撹拌
し、ついで遠心分離して菌体を除去した。得られた上澄
液を中空糸限外過機で1.6に濃縮し、さらにイオ
ン交換水に対して透析した。この液に酢酸ナトリウム
0.5%を加え、さらにエチルアルコール5を加えて
ヒアルロン酸を含む多糖類を沈澱させたのち遠心分離に
より分取した。分取したヒアルロン酸を含む多糖類をイ
オン交換水0.5に溶解させ、4%の臭化セチルトリ
メチルアンモニウム水溶液0.23を添加して生成し
た沈澱を分取した。ついで該沈澱を0.3モル/濃度
の塩化ナトリウム水溶液40mlに分散し、遠心分離した
のち、上澄液に120mlのエチルアルコールを添加し、
生成した沈澱を分取した。この分取した沈澱をイオン交
換水に溶解したのち、イオン交換クロマトグラフイー法
で精製し、7.8gの精製ヒアルロン酸ナトリウムの白
色粉末を得た。培養液1当り5.2gの生産量であつ
た。この精製ヒアルロン酸ナトリウムの蛋白質含有量は
0.05重量%であつた。また、ウベローデ粘度計によ
る極限粘度は〔η〕=17.3dl/gで分子量0,00
5,000ダルトンであることが確認された。Example 1 Glucose 2.0%, yeast extract 0.5%, peptone 1.
5%, 1 potassium phosphate 0.3%, 2 potassium phosphate 0.2%, sodium thiosulfate 0.011%, magnesium sulfate heptahydrate 0.01%, sodium sulfite 0.005
2%, cobalt chloride 0.001%, manganese chloride 0.0
Culture solution of pH 7.0 consisting of 01% and soybean oil 0.5% 1.
5 was injected into a mini jar fermenter having an internal volume of 3.0, heat sterilized at 120 ° C. for 15 minutes, cooled to room temperature, and 0.75 mg (675 units) of egg white lysozyme was aseptically added to the culture solution. And then Streptococcus
Inoculate with 0.1 mg of pre-cultured zooepidemicus, 3 per minute
The culture was carried out for 24 hours under the conditions of 00 revolutions, an air flow rate of 0.7 vvm, and a temperature of 35 ° C. and automatically controlled to pH 7.0. Thereafter, 100 ml of a 50% aqueous solution of glucose was aseptically added to the culture solution, and the culture solution was further cultured for 26 hours under the above-mentioned culture conditions. Then, ion-exchanged water 3.2 was added to the culture solution, and the mixture was stirred. The cells were removed by centrifugation. The obtained supernatant was concentrated to 1.6 with a hollow fiber ultrafiltration machine and dialyzed against ion-exchanged water. Sodium acetate 0.5% was added to this solution, and ethyl alcohol 5 was further added to precipitate a hyaluronic acid-containing polysaccharide, which was then separated by centrifugation. The separated polysaccharide containing hyaluronic acid was dissolved in 0.5 of ion-exchanged water, and 0.23 of a 4% aqueous cetyltrimethylammonium bromide solution was added to collect a precipitate. Then, the precipitate was dispersed in 40 ml of a 0.3 mol / concentration aqueous sodium chloride solution, centrifuged, and 120 ml of ethyl alcohol was added to the supernatant.
The formed precipitate was collected. The separated precipitate was dissolved in ion-exchanged water and then purified by ion-exchange chromatography to obtain 7.8 g of purified sodium hyaluronate white powder. The production amount was 5.2 g per culture medium. The protein content of this purified sodium hyaluronate was 0.05% by weight. The intrinsic viscosity measured by Ubbelohde viscometer is [η] = 17.3 dl / g and the molecular weight is 0.00
It was confirmed to be 5,000 daltons.
実施例2 ブドウ糖2.0%、酵母エキス0.5%、ペプトン1.
5%、リン酸1カリウム0.3%、リン酸2カリウム
0.2%、チオ硫酸ナトリウム0.011%、硫酸マグ
ネシウム7水塩0.01%、亜硫酸ナトリウム0.00
2%、塩化コバルト0.001%、塩化マンガン0.0
01%、大豆油0.5%からなるpH7.0の培養液
1.5を内容積3.0のミニジャーファーメンター
に注入し、120℃で15分間加熱滅菌し、室温まで冷
却したのち、卵白リゾチーム0.73mg(675単位)
を無菌的に該培養液に添加し、ついでストレプトコカッ
ス・エクイの前培養液0.1を接種し、実施例1に準
拠した培養条件、培養方法で培養した。その後、該培養
液を実施例1準拠した方法で精製処理し、6.4gの精
製ヒアルロン酸ナトリウムの白色粉末を得た。培養液1
当たり4.2gの生産量であった。Example 2 Glucose 2.0%, yeast extract 0.5%, peptone 1.
5%, 1 potassium phosphate 0.3%, 2 potassium phosphate 0.2%, sodium thiosulfate 0.011%, magnesium sulfate heptahydrate 0.01%, sodium sulfite 0.005
2%, cobalt chloride 0.001%, manganese chloride 0.0
A culture broth 1.5 having a pH 7.0 of 01% and soybean oil 0.5% was poured into a mini jar fermenter having an internal volume of 3.0, sterilized by heating at 120 ° C. for 15 minutes, and cooled to room temperature. Egg white lysozyme 0.73 mg (675 units)
Was aseptically added to the culture broth, then 0.1 preculture of Streptococcus equi was inoculated, and the cells were cultured under the culture conditions and the culture method according to Example 1. Then, the culture solution was purified by the method according to Example 1 to obtain 6.4 g of purified sodium hyaluronate white powder. Culture liquid 1
The production was 4.2 g per unit.
実施例3 ブドウ糖2.0%、酵母エキス0.5%、ペプトン1.
5%、リン酸1カリウム0.3%、リン酸2カリウム
0.2%、チオ硫酸ナトリウム0.011%、硫酸マグ
ネシウム7水塩0.01%、亜硫酸ナトリウム0.00
2%、塩化コバルト0.001%、塩化マンガン0.0
01%、大豆油0.5%からなるpH7.0の培養液1.
5に界面活性剤としてツイーン80(商品名)0.7
gを加えたのち、該培養液を内容積3.0のミニジヤ
ーフアーメンターに注入し、120℃、15分間加熱滅
菌し、室温まで冷却したのち、卵白リゾチーム0.4mg
(360単位)を無菌的に添加し、ついでストレプトコ
ツカス・ズーエピデミカスの前培養液0.1を接種
し、実施例1に準拠した培養条件、培養方法で培養し
た。その後、該培養液を実施例1に準拠した方法で精製
処理し、8.0gの精製ヒアルロン酸ナトリウムの白色
粉末を得た。培養液1当り5.3gの生産量であつ
た。この精製ヒアルロン酸ナトリウムの蛋白質含有量は
0.04重量%であつた。また、ウベローデ粘度計によ
る極限粘度は〔η〕=15.0dl/gで分子量837,000ダ
ルトンであることが確認された。Example 3 Glucose 2.0%, yeast extract 0.5%, peptone 1.
5%, 1 potassium phosphate 0.3%, 2 potassium phosphate 0.2%, sodium thiosulfate 0.011%, magnesium sulfate heptahydrate 0.01%, sodium sulfite 0.005
2%, cobalt chloride 0.001%, manganese chloride 0.0
Culture solution of pH 7.0 consisting of 01% and soybean oil 0.5% 1.
5 Tween 80 (trade name) 0.7 as a surfactant
After adding g, the culture solution was poured into a mini jar fermenter having an internal volume of 3.0, sterilized by heating at 120 ° C. for 15 minutes, and cooled to room temperature, and then 0.4 mg of egg white lysozyme was added.
(360 units) was aseptically added, and then a preculture solution of Streptococcus zooepidemicus 0.1 was inoculated and cultured under the culture conditions and the culture method according to Example 1. Then, the culture solution was purified by the method according to Example 1 to obtain 8.0 g of purified sodium hyaluronate powder. The production amount was 5.3 g per culture solution. The protein content of this purified sodium hyaluronate was 0.04% by weight. Further, it was confirmed that the intrinsic viscosity by an Ubbelohde viscometer was [η] = 15.0 dl / g and the molecular weight was 837,000 daltons.
実施例4 ブトウ糖2.0%、酵母エキス0.5%、ペプトン1.
5%、リン酸1カリウム0.3%、リン酸2カリウム
0.2%、チオ硫酸ナトリウム0.011%、硫酸マグ
ネシウム7水塩0.01%、亜硫酸ナトリウム0.00
2%、塩化コバルト0.001%、塩化マンガン0.0
01%、大豆油0.5%および界面活性剤としてツイー
ン80を1.5gを加えたpH7.0の培養液1.5
を内容積3.0のミニジャーファーメンターに注入
し、120℃で15分間加熱滅菌し、室温まで冷却した
のち、卵白リゾチーム0.73mg(675単位)を無菌
的に該培養液に添加し、ついてストレプトコッカス・エ
クイの前培養液0.1を接種し、実施例1に準拠した
培養条件、培養方法で培養した。その後、該培養液を実
施例1に準拠した方法で精製処理し、6.9gの精製ヒ
アルロン酸ナトリウムの白色粉末を得た。培養液1当
たり4.6gの生産量であった。Example 4 Sugar 2.0%, yeast extract 0.5%, peptone 1.
5%, 1 potassium phosphate 0.3%, 2 potassium phosphate 0.2%, sodium thiosulfate 0.011%, magnesium sulfate heptahydrate 0.01%, sodium sulfite 0.005
2%, cobalt chloride 0.001%, manganese chloride 0.0
Culture solution 1.5 having a pH of 7.0, to which 01%, soybean oil 0.5% and 1.5 g of Tween 80 as a surfactant were added
Was injected into a mini jar fermenter having an internal volume of 3.0, heat sterilized at 120 ° C. for 15 minutes, cooled to room temperature, and 0.73 mg (675 units) of egg white lysozyme was aseptically added to the culture solution, Then, 0.1 of the preculture liquid of Streptococcus equi was inoculated and cultured under the culture conditions and the culture method according to Example 1. Then, the culture solution was purified by the method according to Example 1 to obtain 6.9 g of white powder of purified sodium hyaluronate. The production amount was 4.6 g per culture solution.
比較例1 ブトウ糖2.0%、酵母エキス0.5%、ペプトン1.
5%、リン酸1カリウム0.3%、リン酸2カリウム
0.2%、チオ硫酸ナトリウム0.011%、硫酸マグ
ネシウム7水塩0.01%、亜硫酸ナトリウム0.00
2%、塩化コバルト0.001%、塩化マンガン0.0
01%、大豆油0.5%からなるpHの培養液1.5を
内容積3.0のミニジヤーフアーメンターに注入した
のち、120℃、15分間加熱滅菌し、室温まで冷却し
たのち、ストレプトコツカス・ズーエピデミカスの前培
養液0.1を接種し、実施例1に準拠した培養条件、
培養方法で培養した。その後、該培養液を実施例1に準
拠した方法で精製処理し、1.5gの精製ヒアルロン酸
ナトリウムの白色粉末を得た。培養液1当り1.0g
の生産量であつた。この精製ヒアルロン酸ナトリウムの
蛋白質含有量は0.03重量%であつた。またウベロー
デ粘度計による極限粘度は〔η〕=12.0dl/gで分子
量628,000ダルトンであることが確認された。Comparative Example 1 2.0% butter sugar, 0.5% yeast extract, peptone 1.
5%, 1 potassium phosphate 0.3%, 2 potassium phosphate 0.2%, sodium thiosulfate 0.011%, magnesium sulfate heptahydrate 0.01%, sodium sulfite 0.005
2%, cobalt chloride 0.001%, manganese chloride 0.0
After injecting a culture solution 1.5 having a pH of 01% and soybean oil 0.5% into a mini jar fermenter having an internal volume of 3.0, sterilized by heating at 120 ° C for 15 minutes and cooled to room temperature, Culture conditions in accordance with Example 1, inoculated with a preculture liquid 0.1 of Streptococcus zooepidemicus,
It was cultured by the culture method. Then, the culture solution was purified by the method according to Example 1 to obtain 1.5 g of white powder of purified sodium hyaluronate. 1.0g per culture
It was the production amount of. The protein content of this purified sodium hyaluronate was 0.03% by weight. It was also confirmed that the intrinsic viscosity measured by an Ubbelohde viscometer was [η] = 12.0 dl / g and the molecular weight was 628,000 daltons.
比較例2 ブドウ糖2.0%、酵母エキス0.5%、ペプトン1.
5%、リン酸1カリウム0.3%、リン酸2カリウム
0.2%、チオ硫酸ナトリウム0.011%、硫酸マグ
ネシウム7水塩0.01%、亜硫酸ナトリウム0.00
2%、塩化コバルト0.001%、塩化マンガン0.0
01%、大豆油0.5%からなるpH7.0の培養液
1.5を内容積3.0のミニジャーファーメンター
に注入し、120℃で15分間加熱滅菌し、室温まで冷
却したのち、ストレプトコッカス・エクイの前培養液
0.1を無菌的に接種し、実施例1に準拠して培養し
た。その後該培養液を実施例1に準拠して精製処理し、
1.4gの精製ヒアルロン酸ナトリウムの白色粉末を得
た。培養液1当たり0.93gの生産量であった。こ
の精製ヒアルロン酸ナトリウムの蛋白質含有量は0.0
3重量%であった。また、ウベローデ粘度計による極限
粘度は12.0dl/gで分子量628,000ダルトンで
あることが確認された。Comparative Example 2 Glucose 2.0%, yeast extract 0.5%, peptone 1.
5%, 1 potassium phosphate 0.3%, 2 potassium phosphate 0.2%, sodium thiosulfate 0.011%, magnesium sulfate heptahydrate 0.01%, sodium sulfite 0.005
2%, cobalt chloride 0.001%, manganese chloride 0.0
A culture broth 1.5 having a pH 7.0 of 01% and soybean oil 0.5% was poured into a mini jar fermenter having an internal volume of 3.0, sterilized by heating at 120 ° C. for 15 minutes, and cooled to room temperature. The preculture liquid 0.1 of Streptococcus equi was aseptically inoculated and cultured according to Example 1. Thereafter, the culture solution was purified according to Example 1,
1.4 g of white powder of purified sodium hyaluronate was obtained. The production amount was 0.93 g per culture medium. The protein content of this purified sodium hyaluronate is 0.0
It was 3% by weight. Further, it was confirmed by an Ubbelohde viscometer that the intrinsic viscosity was 12.0 dl / g and the molecular weight was 628,000 daltons.
Claims (4)
ルロン酸生成能を有する微生物を培養して、該培養液中
にヒアルロン酸を生成蓄積せしめ、これを採取すること
を特徴とするヒアルロン酸の製造法。1. A method for culturing a microorganism having a hyaluronic acid-producing ability in a culture solution to which a lytic enzyme is added, to produce and accumulate hyaluronic acid in the culture solution, which is collected. Method for producing hyaluronic acid.
培養液にて、ヒアルロン酸生成能を有する微生物を培養
して、該培養液中にヒアルロン酸を生成蓄積せしめ、こ
れを採取することを特徴とするヒアルロン酸の製造法。2. A method of culturing a microorganism having a hyaluronic acid-producing ability in a culture solution to which a lytic enzyme and a surfactant have been added, to produce and accumulate hyaluronic acid in the culture solution, and to collect the microorganism. A method for producing hyaluronic acid, comprising:
求の範囲第1項記載のヒアルロン酸の製造法。3. The method for producing hyaluronic acid according to claim 1, wherein lysozyme is used as a lytic enzyme.
求の範囲第2項記載のヒアルロン酸の製造法。4. The method for producing hyaluronic acid according to claim 2, wherein lysozyme is used as a lytic enzyme.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8094985A JPH062073B2 (en) | 1985-04-16 | 1985-04-16 | Hyaluronic acid manufacturing method |
| DE19853531612 DE3531612A1 (en) | 1984-09-04 | 1985-09-04 | Process for the preparation of hyaluronic acid |
| FR858513137A FR2569724B1 (en) | 1984-09-04 | 1985-09-04 | PROCESS FOR THE PREPARATION OF HYALURONIC ACID |
| FR888810752A FR2616802B1 (en) | 1984-09-04 | 1988-08-09 | PROCESS FOR THE PREPARATION OF HYALURONIC ACID |
| US07/336,913 US5071751A (en) | 1984-09-04 | 1989-04-12 | Process for preparing hyaluronic acid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8094985A JPH062073B2 (en) | 1985-04-16 | 1985-04-16 | Hyaluronic acid manufacturing method |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4310954A Division JPH0753117B2 (en) | 1992-10-26 | 1992-10-26 | Hyaluronic acid manufacturing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61239898A JPS61239898A (en) | 1986-10-25 |
| JPH062073B2 true JPH062073B2 (en) | 1994-01-12 |
Family
ID=13732749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP8094985A Expired - Lifetime JPH062073B2 (en) | 1984-09-04 | 1985-04-16 | Hyaluronic acid manufacturing method |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH062073B2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63156707A (en) * | 1986-12-19 | 1988-06-29 | Yakult Honsha Co Ltd | Cosmetic containing hyaluronic acid |
| CN1064372C (en) * | 1994-08-26 | 2001-04-11 | 顾其胜 | The preparation method of sodium hyaluronate preparation |
| JP2008280430A (en) * | 2007-05-10 | 2008-11-20 | Mitsubishi Rayon Co Ltd | Method for producing hyaluronic acid |
| CN116694705B (en) * | 2023-08-03 | 2023-10-20 | 北商加美(北京)科技有限公司 | Ultra-low molecular hyaluronic acid fermentation liquor, product containing same, preparation and application thereof |
-
1985
- 1985-04-16 JP JP8094985A patent/JPH062073B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPS61239898A (en) | 1986-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS60251898A (en) | Preparation of hyaluronic acid by fermentation method | |
| JP2571908B2 (en) | Streptococcus used for production of high molecular weight sodium hyaluronate and method for selecting the same | |
| CN101512006B (en) | Efficient method for purification of high molecular weight hyaluronic acid | |
| DE3531612C2 (en) | ||
| EP0266578B1 (en) | Method of producing hyaluronic acid | |
| HUE029596T2 (en) | Preparation of sodium hyaluronate using a mutant of streptococcus zooepidemicus | |
| CN104120158A (en) | Method for improving fermentation yield of low-molecular hyaluronic acid (HA) by adding hyaluronidase | |
| JPH062073B2 (en) | Hyaluronic acid manufacturing method | |
| JPS6394988A (en) | Production of hyaluronic acid | |
| KR20220111845A (en) | Novel streptococcus strain and hyaluronidase derived from the same | |
| KR101087969B1 (en) | How to produce hyaluronic acid by microbial culture | |
| JPH0753117B2 (en) | Hyaluronic acid manufacturing method | |
| JP3632197B2 (en) | Method for producing high molecular weight hyaluronic acid or salt thereof | |
| JPS6163294A (en) | Production of hyaluronic acid through fermentation process | |
| JPS61219394A (en) | Production of hyaluronic acid through fermentation | |
| JPH0630604B2 (en) | Hyaluronic acid manufacturing method | |
| JPH046356B2 (en) | ||
| JPH0443637B2 (en) | ||
| JPS62257382A (en) | Novel streptococcus zooepidemicus | |
| JPH02245193A (en) | Production of alkali salt of hyaluronic acid having low polymerization degree | |
| JPH0823992A (en) | Method for producing hyaluronic acid | |
| JPS6163293A (en) | Production of hyaluronic acid | |
| JPH027631B2 (en) | ||
| JPS6115698A (en) | Preparation of hyaluronic acid | |
| KR920009494B1 (en) | New Streptococcus microorganisms and method for producing high molecular weight hyaluronic acid using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |